Table 1: Adverse events reported by >4% of patients in the safety population

	Vildagliptin 50 mg daily (n = 177)	Vildagliptin 100 mg daily (n = 183)	Placebo (n = 181)
Any AE	112 (63.3)	119 (65.0)	115 (63.5)
Any gastrointestinal AE	17 (9.6)*	27 (14.8)	33 (18.2)
Upper respiratory tract infection	13 (7.3)	14 (7.7)	16 (8.8)
Dizziness	7 (4.0)	11 (6.0)	7 (3.9)
Nasopharyngitis	20 (11.3)	11 (6.0)	13 (7.2)
Influenza	6 (3.4)	10 (5.5)	11 (6.1)
Diarrhea	2 (1.1)	8 (4.4)	10 (5.5)
Nausea	5 (2.8)	8 (4.4)	9 (5.0)
Pain in extremity	2 (1.1)	8 (4.4)	6 (3.3)
Headache	11 (6.2)	7 (3.8)	6 (3.3)

*$P < .05$ vs placebo

Table 2: Efficacy of other oral agents or exenatide added to metformin

Treatment added to metformin	Duration of Treatment	Baseline HbA_{1c}	Mean change or *placebo-subtracted mean change	Reference
Rosiglitazone 4 mg	26 weeks	8.9%	-1.0%*	(1)
Rosiglitazone 8 mg	26 weeks	8.9%	-1.2%*	(1)
Exenatide 5 µg	30 weeks	8.3%	-0.5%*	(2)
Exenatide 10 µg	30 weeks	8.2%	-0.9%*	(2)
Glimepiride titrated to 8 mg	26 weeks	8.4%	-1.3%	(3)
Pioglitazone titrated to 45 mg	26 weeks	8.3%	-1.2%	(3)
Glibenclamide 5 mg	24 weeks	8.5%	-1.5%	(4)
Rosiglitazone 4 mg	24 weeks	8.4%	-1.1%	(4)
Glimepiride 2 mg	1 year	7.9%	-0.9%	(5)
Rosiglitazone 4 mg	1 year	8.0%	-1.2%	(5)
Pioglitazone titrated to 45 mg	2 years	8.7%	-1.0% at 1 year, -0.9% at 2 years	(6)
Gliclazide titrated to 320 mg	2 years	8.5%	-1.0% at 1 year, -0.8% at 2 years	(6)

FIGURE LEGENDS

Figure 1: Patient flow.

Figure 2: Number of patients experiencing specified changes from baseline to endpoint in HbA_{1c}.

Figure 3: Plasma glucose (Panels A and B) and insulin (Panels C and D) before (Baseline, Panels A and C) and after (Endpoint, Panels B and D) 24-week treatment with vildagliptin 50 mg daily (open triangles), vildagliptin 100 mg daily (closed triangles) or placebo (open circles) in patients with T2DM continuing a stable metformin dose regimen. Patients from the primary ITT population who participated in meal tests (n = 54 to 58 patients per treatment group).

Figure 4: Adjusted mean change from baseline to endpoint in fasting lipid parameters (Panel A) or body weight (BW, Panel B) after 24-week treatment with vildagliptin 50 mg daily (shaded bars), vildagliptin 100 mg daily (black bars) or placebo (white bars) in patients with T2DM continuing a stable metformin dose regimen. Primary ITT population, n = 130 to 143 patients per treatment group. * $P < .05$, *** $P < .001$